Randomized, Double Blind, Comparative, Parallel group study of Vitamin D3 ( Cholecalciferol ) Vitamin K2-7 & magnesium in prophylaxis of COVID-19 infection in health care professionals - Covid19

Suraksha Pharma Private Limited0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

研究概览

暂无简介。

•1.Participants of either sex, 20 to 60 years of age who are at high risk. High-risk individuals are defined as all health care professionals in hospitals, clinics, and emergency rooms, and medical facilities involved in management of COVID -19 patients.
•(Doctors, nursing staff, paramedical staff, ambulance staff, other hospital staff, ward attendees coming in contact with COVID -19 patients).
•2.Participants who are negative for RT-PCR test for COVID-19 infection
•3.Participants who are willing to provide inform consent and willing to come for schedule follow up visit.
•4.Participant not having contra indication to take Vitamin D,
•5.Participants having no COVID- 19 infection clinically.
•6.Signed informed consent, demonstrating that the subject understands the procedures required for the study and the purpose of the study.

•1Participants with known allergy or contraindication to Vitamin D ,Vitamin K2-7 & Magnesium .
•2History of having received any investigational drug in the preceding one month.
•3History of taking any kind of formulation or any other form of therapy for COVID- 19 prophylaxis.
•4Unwilling to come for regular follow-up for the entire duration of the study.
•5Any condition that, in the opinion of the investigator, does not justify the subjectâ??s inclusion in the study.
•6Participants participating in other clinical study.
•7Participant receiving other immune enhancers.
•8Refusal to sign informed consent form
•9Any previous positive test for COVID-19 by RT- PCR
•10Symptomatic for COVID-19

发起方

Suraksha Pharma Private Limited